MAbxience and HP Collaborate on AI in Biomanufacturing

mAbxience, a Fresenius entity, and HP Inc. have announced a joint project aimed at developing an innovative AI solution for the production of monoclonal antibodies and biosimilars. This project signifies a pioneering move in applying AI to industrial biotechnology, creating a digital twin that enhances production predictability, consistency, and efficiency.

Sergio Martínez from HP highlights the project's potential in optimizing processes and improving access to critical treatments. The collaboration aims to bolster mAbxience’s role as a competitive biomanufacturing partner by enhancing operational efficiencies. Insights from real production data processed through advanced neural networks have produced a tool for simulating and optimizing manufacturing stages, potentially increasing yields and reducing variability.

This initiative marks the beginning of strategic collaboration efforts, with intentions to apply AI across mAbxience's operations globally, thus enhancing productivity and sustainability.